Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos ...

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...

Ocaliva recently failed to secure the FDA’s traditional approval for primary biliary cholangitis due to safety concerns.

The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to ...

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence ...

Kerros stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure ...

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a ...

The EPIC Act has been proposed with bipartisan and industry support to give small molecule drugs the same protection against ...

Pourhassan and Kazempour are awaiting sentencing but could face up to 20 years in prison for each count of securities and ...

Lago, leaders at Pfizer and Eli Lilly have publicly stated that they intend to collaborate with the incoming administration ...